Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cancer Genetics, Inc. Merger (Tables)

Cancer Genetics, Inc. Merger (Tables)

6 Months Ended

Jun. 30, 2021

Business Combination and Asset Acquisition [Abstract]

Schedule of Preliminary Allocation of the Purchase Price Consideration

The following details the preliminary allocation of the purchase price consideration recorded on March 31, 2021, with adjustments recorded in the second quarter of 2021 and balances as of June 30, 2021.

	March 31, 2021		Adjustments			June 30, 2021
Assets acquired:
Cash and equivalents	$	30,163	$	-		$	30,163
Accounts receivable		705		-			705
Other current assets		806		164			970
Intangible assets		9,500		-			9,500
Fixed assets		416		(15	)		401
Goodwill		22,164		(461	)		21,703
Long-term prepaid expenses and other assets		1,381		-			1,381
Total assets acquired	$	65,135	$	(312	)	$	64,823

Liabilities assumed:
Accounts payable and accrued expenses	$	2,670	$	189		$	2,859
Current liabilities of discontinued operations		588		(141	)		447
Obligations under operating leases		198		-			198
Obligations under finance leases		106		-			106
Deferred revenue		1,293		-			1,293
Income taxes payable		360		(360	)		-
Total liabilities assumed	$	5,215	$	(312	)	$	4,903

Net assets acquired	$	59,920	$	-		$	59,920

Schedule of Proforma Financial Information

The following presents the unaudited pro forma combined financial information as if the Merger had occurred as of January 1, 2020:

	2021			2020			2021			2020
	For the three months ended June, 30						For the six months ended June 30,
	2021			2020			2021			2020
Total revenues	$	1,947		$	1,545		$	3,788		$	3,139
Net loss		(4,021	)		(2,689	)		(5,560	)		(5,799	)
Pro forma loss per common share, basic and diluted		(0.14	)		(0.09	)		(0.19	)		(0.20	)
Pro forma weighted average number of common shares basic and diluted		28,985,924			28,830,441			28,973,370			28,826,652